


In the Claims:

1. (Currently Amended) Peptide derivatives of the formula I



in which

X¹ is Ser, Gly or Thr,

X² is Leu, Ile, Nle, Val or Phe,

X³ is Asp, Glu, Lys or Phe,

X⁴ is Gly, Ala or Ser,


X⁵ is Leu, Ile, Nle, Val or Phe,

X⁶ is Arg, Har or Lys,

R¹ ~~is absent or~~ is one or more α-aminocarboxylic ~~α-aminocarboxylic~~ acid residue(s), the α-aminocarboxylic ~~α-aminocarboxylic~~ acid residue(s) having a length of 500 to 2500 pm,

where the amino acids mentioned can also be derivatized, the D and the L forms of the optically active amino acid residues are included, and their physiologically acceptable salts and solvates.

2. (Original) Peptide derivatives according to Claim 1, of the formula I



in which

X¹ is Ser, Gly or Thr,

X² is Leu, Ile, Nle, Val or Phe,

X³ is Asp, Glu, Lys or Phe,

X⁴ is Gly, Ala or Ser,

X⁵ is Leu, Ile, Nle, Val or Phe,

X⁶ is Arg, Har or Lys,

R¹ is absent or is 1-10 amino acids selected from the group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Hcy, His, Hse, Ile, Leu, Lys, Met, Pen, Phe, Pro, Ser, Thr, Trp, Tyr, Val and



m, n in each case independently of one another are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, with the proviso that m + n is > 0,

where the amino acids mentioned can also be derivatized, the D and the L forms of the optically active amino acid residues are included, and their physiologically acceptable salts and solvates.

3. (Previously Presented) Peptide compounds according to Claim 1 selected from the group consisting of

cyclo (Arg-Gly-Asp-Leu-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-Asp-Gly-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-D-Ala-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha-Aha),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aee),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-β-Ala),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-β-Ala),

and their physiologically acceptable salts and solvates.

4. (Previously Presented) Peptide compounds of the formula I according to Claim 1 and the compounds selected from the group consisting of

cyclo (Arg-Gly-Asp-Leu-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-Asp-Gly-Leu-Arg-Gly-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-D-Ala-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha-Aha),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aee),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg- β -Ala),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg- β -Ala),

and their physiologically acceptable salts and solvates, as medicaments.

5. (Original) Medicament according to Claim 4 as an inhibitor for the control of disorders which are based on an expression and pathological function of $\alpha_v\beta_6$ integrin receptors.

6. (Original) Medicament according to Claim 5 for the control of thromboses, cardiac infarct, coronary heart disorders, arteriosclerosis, tumours, osteoporosis, fibroses, inflammation, infections, psoriasis and for influencing wound-healing processes.


7. (Previously Presented) Pharmaceutical preparation, comprising at least one medicament according to Claim 5 and, if appropriate, vehicles and/or excipients and, if appropriate, other active compounds.

8. (Previously Presented) Use of peptide compounds according to Claim 1 and/or their physiologically acceptable salts for producing a medicament for the control of disorders which are based on expression and pathological function of $\alpha_v\beta_6$ integrin receptors.

9. (Original) Use according to Claim 8 for producing a medicament for the control of thromboses, cardiac infarct, coronary heart disorders, arteriosclerosis, tumours, osteoporosis, fibroses, inflammation, infections, psoriasis and for influencing wound-healing processes.

No fee is believed to be due with this response, however, the Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Richard M. Lebovitz, Reg. No. 37,067
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2360
Date: October 24, 2005